Sources of funding of the Women's Health Program

All research carried out within the Women’s Health Program in the Department of Medicine at the Central and Eastern Clinical School, Monash University is approved by the Monash University Human Ethics Committee. For studies involving patients attending the Alfred Hospital site, approval is also required from the Human Ethics Committee of the Alfred Hospital. As part of this approval process ALL sources of funding are clearly stated.

Sources of research funding include:
The main source of funding for the Women’s Health Program in the Department of Medicine at Monash University is from the Commonwealth Government in the form of a Centre of Clinical Research Excellence (CCRE) Grant from the National Health and Medical Research Council (NHMRC) of Australia. We also have two PhD students on National Health and Medical Research Council Post-graduate Scholarships independent of the CCRE.

We receive funding for the ATLAS (Adjuvant Tamoxifen Longer Against Shorter) study. This is a multicentre involving multiple centes in Australia and internationally study funded by Clinical Trial Services and Epidemiological Studies Unit (CTSU, Oxford UK

We are running a number of studies funded by sponsoring pharmaceutical companies. Current studies in this category include a study of transdermal testosterone sponsored by Proctor and Gamble and a study of the effects of female sexual dysfunction in premenopausal women sponsored by Pfizer

The program has received several philanthropic donations (unidentified by request) dedicated to the funding of the After Breast Cancer Study. We have also received philanthropic support for a randomised trial of Dehydroepiandrosterone (DHEA) which is also partly sponsored by Endorecherche Inc in Quebec, Canada.

Other financial disclosures:
Susan Davis has acted as a consultant for Cellargy USA , Vivus USA , Procter & Gamble Pharmaceutical, Acrux Australia and Organon Netherlands